Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Trastuzumab in patients with Invasive Breast Carcinoma.
Health Canada approved trastuzumab for metastatic breast cancer in patients whose tumors overexpress HER2.
This statement is based on a regulatory approval from the Health Canada:
HERCEPTIN (trastuzumab for injection) is indicated for the treatment of patients with metastatic breast cancer (MBC) whose tumours overexpress HER2.